0001193125-24-174334.txt : 20240702 0001193125-24-174334.hdr.sgml : 20240702 20240702161403 ACCESSION NUMBER: 0001193125-24-174334 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240627 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20240702 DATE AS OF CHANGE: 20240702 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VERU INC. CENTRAL INDEX KEY: 0000863894 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 391144397 STATE OF INCORPORATION: WI FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-13602 FILM NUMBER: 241095409 BUSINESS ADDRESS: STREET 1: 2916 N. MIAMI AVENUE STREET 2: SUITE 1000 CITY: MIAMI STATE: FL ZIP: 33127 BUSINESS PHONE: 3125959123 MAIL ADDRESS: STREET 1: 2916 N. MIAMI AVENUE STREET 2: SUITE 1000 CITY: MIAMI STATE: FL ZIP: 33127 FORMER COMPANY: FORMER CONFORMED NAME: FEMALE HEALTH CO DATE OF NAME CHANGE: 19960205 FORMER COMPANY: FORMER CONFORMED NAME: WISCONSIN PHARMACAL COMPANY INC DATE OF NAME CHANGE: 19920703 8-K 1 d838156d8k.htm 8-K 8-K
NASDAQ false 0000863894 0000863894 2024-06-27 2024-06-27

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 27, 2024

 

 

VERU INC.

(Exact name of registrant as specified in its charter)

 

 

 

Wisconsin   1-13602   39-1144397

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

2916 North Miami Avenue, Suite 1000, Miami, Florida 33127

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (305) 509-6897

Not Applicable

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, $0.01 par value per share   VERU   NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


Item 5.07.

Submission of Matters to a Vote of Security Holders.

On June 27, 2024, Veru Inc. (the “Company”) reconvened its 2024 Annual Meeting of Shareholders (the “Annual Meeting”) that had been adjourned on June 18, 2024. A total of 146,381,186 shares of the Company’s common stock were eligible to vote at the Annual Meeting. A total of 77,933,668 shares of common stock were present or represented by proxy at the reconvened Annual Meeting, which represented a quorum. The only matter submitted to a vote at the reconvened Annual Meeting was the election of directors and the voting results for this proposal are set forth below.

Election of Directors.

The following individuals were nominated for election to the Board of Directors for terms that expire at the next annual meeting of shareholders. All of the nominated directors were elected. The results of the vote on the election of directors were as follows:

 

Name

   Votes
For
     Votes
Withheld
     Broker
Non-Votes
 

Mitchell S. Steiner

     75,509,396        2,424,272        0  

Mario Eisenberger

     71,473,307        6,460,361        0  

Harry Fisch

     76,388,868        1,544,800        0  

Lucy Lu

     62,897,925        15,035,743        0  

Michael L. Rankowitz

     63,804,466        14,129,202        0  

Grace Hyun

     64,168,941        13,764,727        0  

 

2


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: July 2, 2024

    VERU INC.
    By:  

/s/ Michele Greco

      Michele Greco
     

Chief Financial Officer and

Chief Administrative Officer

 

3

EX-101.SCH 2 veru-20240627.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 veru-20240627_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Security Exchange Name Security Exchange Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 4 veru-20240627_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.2
Document and Entity Information
Jun. 27, 2024
Cover [Abstract]  
Security Exchange Name NASDAQ
Amendment Flag false
Entity Central Index Key 0000863894
Document Type 8-K
Document Period End Date Jun. 27, 2024
Entity Registrant Name VERU INC.
Entity Incorporation State Country Code WI
Entity File Number 1-13602
Entity Tax Identification Number 39-1144397
Entity Address, Address Line One 2916 North Miami Avenue
Entity Address, Address Line Two Suite 1000
Entity Address, City or Town Miami
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33127
City Area Code (305)
Local Phone Number 509-6897
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.01 par value per share
Trading Symbol VERU
Entity Emerging Growth Company false
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://verupharma.com//20240627/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d838156d8k.htm veru-20240627.xsd veru-20240627_lab.xml veru-20240627_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d838156d8k.htm": { "nsprefix": "veru", "nsuri": "http://verupharma.com/20240627", "dts": { "inline": { "local": [ "d838156d8k.htm" ] }, "schema": { "local": [ "veru-20240627.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "veru-20240627_lab.xml" ] }, "presentationLink": { "local": [ "veru-20240627_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://verupharma.com//20240627/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-06-27_to_2024-06-27", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d838156d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-06-27_to_2024-06-27", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d838156d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://verupharma.com//20240627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://verupharma.com//20240627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://verupharma.com//20240627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://verupharma.com//20240627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://verupharma.com//20240627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://verupharma.com//20240627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://verupharma.com//20240627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://verupharma.com//20240627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://verupharma.com//20240627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://verupharma.com//20240627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://verupharma.com//20240627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://verupharma.com//20240627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://verupharma.com//20240627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://verupharma.com//20240627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://verupharma.com//20240627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://verupharma.com//20240627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://verupharma.com//20240627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://verupharma.com//20240627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://verupharma.com//20240627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://verupharma.com//20240627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://verupharma.com//20240627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://verupharma.com//20240627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://verupharma.com//20240627/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001193125-24-174334-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-174334-xbrl.zip M4$L#!!0 ( ,&!XEAVH#A8MA ")\ . 9#@S.#$U-F0X:RYH=&WM M/6ESXDBRW_TK*I@W.W8$AR1N;+-!TW0W.S[Z@>>(]V6BD I3:R%IJB0;]M>_ MS)($XI#!&%^].,(VHJZLO#,K"\[^.1G;Y)X)R5WG_!<]K_U"F&.Z%G=NSW]I M]=O=[B__;!Z=C7SH!ET=V; 8/\^,?-]K% J3@;#SDIGY6_>^ T%0S.*F:AC M('/^U&-RUGM(Y2#OBMM"W++0W7$=)QC/.C\\/.35]#C \D4!1Q2@4PYZ,<'- M>-S$YL[=PK"'HAJDU^OU@FJ-NZ[TG"U@:%JQ@,T#*EG<'= 2S+KC@S>B8DSS MICM&R$M:Q:C.H)!\'0PPKU[X\_*B;X[8F.:X(WWJF+,5 E^DPE,O0&OLP&3-+ZZM#7@:VR/S_U+N;=_?7]YUT+OJ".'+J 1^8!6%!4A6()LOVAHS MQX)?_XM-;Y^ZFMHAG]SGBJ5BICFDMF2;5E["2<QV.17-DTB M):7#$[&BP4^M4JS52ZOP%98(*-B0"="L3,(S*IJ&5"H!UGI)/:960LUYGI%\ M[-FS]T8"-XE*+1>KLOQ$6G$S%:9PD4C%"OG=\#"KK6[!%4C? _4Y\U MY[#%(^=MS,L#G'7B&I& J@0.!?0HW@J!RU^:W3,&$O M3&06VQ^XY8\:M7R9.Z>)OC8;^J=C*FZYD\/7#4(#WXW?$?QV%+V%TWGQ9*C% MD4[ M/2MX:0L5-R]D[+Q08MH23$)6-T"&0)JQ[2,;>GC1L^9I)V3M>0Y[>K[DWG,^G?M&XZ_71PM%<"I]]I_];KWG0[?=*Z M^DPZ?[:_M:Z^=DC[^O*RV^]WKZ^>!:.Q#QC_H'($/JGO.EGR.=_.$T,KE^I+ M<"TMNHDS%QEBDT2MYAE)JZ#^O[GY+*9UO)E82ZP@6DN,5 MN.K+=>^2G$F/.C-%-.(^R\$[)@-C^2"HEVFFNA"?73- #R+A7>W@091+F="+ M6[3/9P6$JWE@GQ=AG[T(/*BD7N?JAO0ZWZ][-V^O@+X'0@;4\8GO$O"ID0%# MC.E%X@JBEX^MD[>'TAT2?\1(Y/1S&!_[_:1E^@2:]7JQE [GJY$7?2$$I\<\ M5_CD.'YF%'PA)GW"[J$G$:J962>-]& CUA3?E4/5"?VL)ZN,,"!%M>$W+)A@ M#,-'%IU. 2+FS%4*A+O-?P4.6]!L:H,6,]UPF48 (85 0<_$JH88U2S!]595 MT4$'[5\'&:5],&DJRX7Q8X_=]7.;^"/I^D4 M;1]8..Y,*.@.W#U*J)CMFE!)I,=,C*.#K%+Y^#F*. MSGPZL!DQF6VC6X5)VXR64<\>M:SX.5HJVJKIVC;U)&O$+QYGD00_H5\8(D/7 MM)\CU#6T",J&%H>+ )=0?ZW%&+18^AG3!R9\;E([PFJXT>5.T6ACN]$Q MB"N]D].<%2(01=SJT5N6&PA&[S!-RRW6H/196) F&(0LUPV:1:+9;"+?W )\TONI/K;OK4-^6<\OMS]1?"Y3E3H>S9Z*QEFL5Z3M=+I6*]N@5&7T ;U/:C M#'8U_7L)X8^5_L#PQH6H0I!_0U A+:Z"GR?Y)?H+ >N"$_JNI/0O+Z%?+PM MD=KN>,RE? \T05U(0NG]KR5'M]J9IE'7*X -X8_()0>P2>N>.<'*.6,V M/>N0!IBQ.V 5+=/L!V ^";C7VJZPM.'EM;AQ'YQG0*)GF@HONP*A#,>U^ Z> M(E 'MRC-F$39@8^O\>@'A0$DR?D&)! $ N/9#)?327,LRO_^*EF MZ-53"<; 9M[(=1AQE(W)H@=@!QCG$@J^&M .'+5TLJ-HM*#?,PE= I06M?+) M*K_M[ A?N&##ON/6GNO[5LJ99EFKYRJU1SS?-R?NE>N3EN?98)C ^KR]A'P! M?0,.;ICC$DK]P",-Y0;8;$C"+#HX)JC/B$UEG)S.'U)=+W.,M(G1,LWVB)EW MZL"#>F <0+=AN#)P)V3 ;/THDB*0<3M4*T0!W /@*/:WH(":1+%5G H0ZT[AMZ-H )(Y# MP\;1@9?D6#)&OC*'"5#170?&!BK<(JV\D0^W==)(9;C*KAG$?64(]7G!1T-+ MY I7Z>?3M3F+-%7[A^ ^$!6CIL")'&/Y; =EX+KV@ )! M?6"_I#JN(+[KU5+I=%4;;PB.EH,9LDA:\FQ-O50-E&E&N %D))%#O,399R\ M=BD9Y8B?ETX;\9#Q6*^2]I<>,8I:'CIN#C@._/L4_NV#PC8!V\[M)6@[4'GV MRS%O]2,Q[QPQ,'6(F57.W6@&]!+-Z49L">9,OG".'K/XQMF,DI8/9SQ).%\' M:=B;-'P7##4YUIVJ:B&TUN)Z.-S!A=Y:*FH?22HVLBA@,&'"R7UD*YSQ(TVM(4U?*@(E7D:GZ0::VDJDBRY6.S?W*5#3GUC*U]S@N MX4"& 1,3$')YJ15WJ 'B* JVFQX/'4HJ/G9)Q0Z'J%LD.5*VN$8\WO3LY@8O MGH4UD>:(F#:5\G7.U'9%X1N?O-T(BN+YYF=N_>D8FH[E*YV ?E!J747EA(JY M662\WIQVKD- #P!$ZI'3#BX8V\$14KIZAO5+24AI-(3X1B^@R$Z&'5[OO8[:*K M1]#9SO%)+KR"VMAT7SBZX$O:U.,^MHM MB?GEB"(Y1L)43U7Z,N[,56&SAX7->#ZTI;-N#'*S3-)V-S,V3QI#AX[[ROP) M,/,O?,J78%)U_I-I=E*(L.$4/A[V58UJAX->+-"L&H\$FB^),&#LX2.LBD?9 M:_F>KQPDC8"KF0T!$7"UXZKP*)!,]0*$1<=5^!D+7!T,$4%J+7N*BS]P M6!J)XP!\T"+8/9%I:71F>G2TG@_9>(4-\:V$'S)@0&CP0^P' M.I5H%F#JH[/1S&6! -45C9_JZNT89#Z?W>-3]: MSKM]NNY][O1R[>N+B];W?J<1OWC/>3==6YMX(^HE<-)J%FFUJKKKLS%6OFCZ M:3FO5?.K%>#)V=XJ-_:84QT=RP2#J#P5=<,E]8%I).H-2GYWPTM_L4]"OL$, MT)HG3\E!55*4LX($M"JP*29"GZ:LKQV"M_Q"^8SO[F7)[TP$I.N8>7*,6@[I M8VBGD=%23_KI"6A3L%[W3+D=OE1#2-OO(HW/'"=(M=9[/Z M(XK*WR(#QAQ"K7^[@< EW"2H>BT$-4]:@&/TY="S*%6RQ9J>U6N5T$.7L9I. M0*XJK,S0PY?HX9,'"'_ TO!;CN((%+M'>@$0*N^V .3"R83ROD(FB\D>#5*,A3"F MLHV:@LIHW[*QC.-73%_OQ[9&1K^4GKX^.@H3V$=K;&6EBLGCHZV3T/.$]_*_ M]S+'JR3"MTYBQV["FAK"K;R!+?*+)/XDL_!3WG(#&Y3\DW)S*0G"'3*H*UD5 M\'A1EYUGC&54+!WB[)!!10=&G@U$H?G%%<]._+S'??T!@>*(V=8/M+E/PKUC M0NUN8[;ERG5R(3)VOW^IU$&D ?>:.3X=4//N5D"8;N6BN,XT&1L.'U<5.\4$ MR> -D8UA9]+!SL5O/LG\7W+?!.ZR23]/^CX#W2'V(?*I!$UCB6?/$#-IE JK MEK-EK9XMUBLO =4'0X:1+4'H9%2- RZ:VIZ >9VSJ'>L.*C@+NEP"/L&3-S^ M*&I#SY:JQ6Q1JQY$I5G)EBI:MEC1#[AX[VKCXSLBWZ@04_*%2W/T8V@23/C5 MLK5*[2 ]33U;+I6R-6U?4O21=._>!^__Y,71*$0QN"5SX M0P8$;T)E=:.>-;1#"N3=ZY0/HSJ^"D 7^38-G!]#88",5&K9>ND0[^,UKVP5 M$%(U#HF@/2N,HUDMT5'Z18,5&28K9[&;ODID\RV*)Y78QH>B1E@L<'24+!<\ M@KW\5U<,ONG'8_>[7Z]:-[_U.OW'2GK2*HB?5:26_$Z"L)#I[X +=>-4;EEP MGEU776P%]I28-,"*8%7)%'[2$2XS8$3"[L.R,RQN&[ 1M8=8M843J;JBJ,.( M"18X,$9-![0:N0(V9JT4%7W0@I>%"YN/U[B4RD^K<4F[:%G:;$I6>^R[VYM%"3O2ZB7H_V2:?YHV7H:#]W#)>L.5 MBB?*<$$6".9@&)B0KU@'_,JW/3\NX[P:,RZ1YT":]T.:%W.\\:,=.1N2+[/K M:-?J,VKQ\Q.MYUP2WWKEEC7FCO*)U4?D1LLO:HEA<5F@UCM)D$ &J7!="S<=1 M;6-N8P2$;,L(= MP&$V2+.#=_#E$WP,3A1GY3!V^%A#UZ@6*&#((MY,M?7C SKKKU=/!S"<# 8,>H&1UG& M'D4*]=\.AC=/J3'ZAVQ0;D:!D!X=';%@79-4N/L1M-[?L,88T-PY(Z:UPS-M MRE.<\5H2JU;_UUR*F< BH*A+2U3N'N8^PG$S1W?)2[05S_$1B:9F>B@J$IJR M?S]=? U]%IUX D!H/5%6VCAH.O!"Y^%>[$BF_XJ[&L1^*TZ'\2A-R%D$:D/S MC@(">[:0KK1/$K+JB[V%V&W]ZQ>Q7VP[_>&N?W(&UB^SC__(QY^^W2O^C6'P M"Y1H=?E<,;V)]O2:*"[R9F UR_WK'2'MJ.),KI5TX MJ*^$5Y50,]UNT:9OXJSKY G.( ROC)O<:(F[1QRKC*[0.$$#_NXR- X6!F?C MR$^OES#M]%)RN7+MVV$< M6]9<>ZM'!^W.N" %^\6URONUU6#T/S/%; MK72Y;"2>ZKSV[T_W_X,J/BH2MCRGOB*R%Q6!H'=D0O#O>\%7$CN1!=*O-A&: M-QWX/_I1UWGH+[DJH'$'/7_';-W)NO_:8O%9G81USF5>RU7*6W*+V$5<+];^ MS#MEVWGM;E>N[A*S]5O<[O1O>[/53!OZ_ %02P,$% @ P8'B6-Q?^"=^ M!@ N$8 !4 !V97)U+3(P,C0P-C(W7VQA8BYX;6S-G&]OVS80QM\7Z'>X M>6\VH+)CIT!7HVF1.]8?^H!X0%/*1L?M);2<^7 :4]D(G/ M0C_BC)STMD3V/KQ_^>+=#YX'9Q>7G\"#19(LY7@P6*_7_?".,LFC5:(D93_@ M\0 \KXB?3+_ 'UFY,7PF$?$E@=B7"1'PZXI&X7AT-#H>'@U'_5$Y31!?ZT'H M)V0,;P:C@8I[#6_&1\/QZU_@YB._K" O(^E8IONO>)">08L&H3)"_^0589[>Y0U' MWO&POY%A[[TNF)\=?T:B*[4%J8>QX!&I*:P/I]5[>7RR7:IXLDD("TFN_$V; M!WG40I"[3%6CETI*$O3G_'X0$JH!.=8;GM[0'?ZH?O@ZX8KVTYE,A!\DN_4B M?8JX*':F)DYZAJ3!;D,Z[E0$.UJ^" H=M7G ?QXQ"+CZO2T3+U4LTN\$CXU= MY.6XX>#7:!89V]0DJ2T]W(1Y7VX/>I,OQ3:/_[ M;O!0^[FTJEY")+EJVJ\;DK%'E^I*8O,[V=IB69'<$9[U M5GA-D NN-8)(V&85("\!:0U019P!;K'U,LC-^W=#^HP'*STW4]6]+*;>EC?E\5%RQV": MK?":( Q4#8+8S&8E0-4 700-WQ9:-W)LW3_&Q<)G,J?ZW1Y+FKP),^=V>JE0 M8817Q[A?*)CT<*\3'BK@O EKKV_#18)U\Q@@7[* BR47Z3V_VT0-SH2OU$7* M=L+#AEP?D.H4T>PISU.HK13I%.%#UKA%L#O MVD%_Y(K^Z-FA/[)%?]0&^J/OA_YTS5M#'\F&-?JU7A#1GZC-:S'E:_8D\,OI MSP%[@QT3] ]A:,@_EFP)>%T&N !="!=V; -UJ-NY0,0\?3]\+6X$OZ$YC(+9E&D0=B+1QL"@VM(09)5 E<*\;]F>C;H!L/;B^&%6;5 0OPGP MNSE=?935U#C?/^;T0=8]'21PT__GM3(.I_A][GR(U;)9-Q#UI\NCFP5G#>^7 M[^=U!&2E 6X^[@*F60L)SE0<4G6L^X;M]%N&M$G3;J#^*6B2$#;A<;QB^?U( M:4MK17)'R-9;X35!+O#6""(1G%> W1+.%+?8>!GEIMT[+AW@$0UH0MG\H[KB M%M2/;%DV97:U;*#:!*^*<%HR4*&&Q.^#/!3Z[JL%6FIY9ZU D[[=L+T11,\' M45BDGX34R[S$]=V=_85#G4)'&%N8XH1P-)O2)&J\*O(AK^,5D7L&N/DXQDK(72VLBYIB(:%2AU0>;04D;K_&U8\6 M3;N!.A6^_LJ$VVT\X]:7X(^2.D+4W#HW''2!TR"$1&:N#)FT,Y4M-%I&TK9; MC,2FD1R,MVC \&['U4MYQI;;T5Z[DNVCVQ2-JS_]02P,$% @ P8'B6$L@ MA6_(! .BP !4 !V97)U+3(P,C0P-C(W7W!R92YX;6S5FF%SVC88Q]_W MKM]!\]YL=S,&DS8-%]IC)-EQ(PD'=-OM34_8#Z";+/DD$^#;[Y%!+0:30MKM MK+P((.O_Z*_G)V1+Z/K#*N'D"91F4K2]1JWN$1"1C)F8M;V%]JF.&/.(SJB( M*9<"VMX:M/?A_>M7US_X/KFYZST0G\RS+-6M(%@NE[5XRH26?)%A2%V+9!(0 MW[?UN^./Y(]-,QZVP'C8;]498"W=E"JB)1V*:08M< M!F& ]2[(9:O>:%V\(X-[D9^BGTDNNI%" .>P)G=, M4!$QRLG(&OZ%]$14(QW.R=#(-+K4H)X@KFVC MVO9,,K:Y6$T4KTDU0[?U9F!%WJYF=2!:-G-)X^KJ*LBO%NMK5E8;&V@$?]WW M1]$<$NHC D06[36%;N+LLWK7W)M@<]'6UZRE\TA]&>69/Z%;Y&@-\\FWU7Q3 MY#="O]FHK73LO3=-;K*J)(SK;\/+(*,K M*62R#HPBN)'1(@&1V=>.B&]%QK)U3TPEBDT_/)*GM#57,&U[)K!OHQDW/PXQ MT*=S F7K%+\4FB4I!X\$.[U)%8X6U^UA0$, J Q%#;,.8#OPG_7V_(;H= MMC(J]-]^;W-<&J+:3#X%,3#38M.\,!FG$AE M"SF= &][):+@>QH:0;10V.';532G8@8/-(%3?95KB_9V$7945(A,562CXML" MO\-OP+9&D%*%\?QHCE.=54^53$I3M6U-/N=7JAA4VPO#&DX 'DD5DZ82EGAD MH=&23(UYRLTUF()2$/*DZF&O.9W9M;!H1J;X7K'Z>Q46'NBZE+: M,VKQ-)W!LYE!NM@#17D/IZC5[[ ^%=,1<75Q'3%LL5TX@\W> \:8QE-I%375 MA53T:=F\=8[- - KWJ+C&WR*/1?2GKCZM/8,6VR7SF#;S U#F#'349&=\W!1 MKJTNM'*_EMD[QYCA$DZJ5*H\M2/,,'3E J?X=5?&9R+\2JBJ$_V*?0OXRC' M=XS#PR*9@#J/YJZNZNAVO6XY->N.<1K352_&-+ IVVPCO 3:T2!5)WC4N,79 M< QG)XXQR7K[TF<"&N>A+ U0=8REIBU"=];=QSH3?BO"T$6$X1>$KJW-M[WH MXMM'-99+\2* NW)'\.U:MO#<6:$7NI(_BCVJ@9)/S&S3OX3@00Q',![XMBS? MN,ER('5&^=\L/7]U41[!$8Y[KBU%=_9ES'S244#/X5;45)=4T:=EX\[FB_G= MD0_F4IRYSCO459?1H5?+R9T-ES_17P:B*Y-D(;;+''TJK"/BZA([8MAB;\:*&6LG_FQ:HJPNL#*W6UH7[FRF#!28(0?XM)3_#F).#JC' MZ?3T:?&Y"-6E]YQK2]&=/92]WO2T7H#Z=I8E<9PA6N+=S&B$DS'+ M^-D'4+[HJLOMT*OEY,[NR5A1MU<,?_,$4XL^1=0 M2P$"% ,4 " #!@>)8=J X6+80 B? #@ @ $ M9#@S.#$U-F0X:RYH=&U02P$"% ,4 " #!@>)82;GXZT # !%"P $0 M @ 'B$ =F5R=2TR,#(T,#8R-RYX)8W%_X)WX& "X1@ %0 @ %1% =F5R=2TR,#(T,#8R M-U]L86(N>&UL4$L! A0#% @ P8'B6$L@A6_(! .BP !4 M ( ! AL '9E XML 16 d838156d8k_htm.xml IDEA: XBRL DOCUMENT 0000863894 2024-06-27 2024-06-27 NASDAQ false 0000863894 8-K 2024-06-27 VERU INC. WI 1-13602 39-1144397 2916 North Miami Avenue Suite 1000 Miami FL 33127 (305) 509-6897 false false false false Common Stock, $0.01 par value per share VERU false